What is the recommended dosage and titration schedule for isosorbide mononitrate (Imdur)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Imdur Dosage for Angina

For chronic stable angina, start isosorbide mononitrate (Imdur) at 30-60 mg once daily in the morning, then titrate up to 120-240 mg once daily as needed for symptom control. This once-daily dosing regimen prevents nitrate tolerance while providing 12-hour antianginal coverage throughout the day.

Initial Dosing and Titration

Start with 30-60 mg once daily in the morning 1, 2, 3, 1. The lower starting dose (30 mg) helps minimize initial headache, which is common but typically mild-to-moderate and improves with continued therapy 4.

Titrate upward based on response:

  • Increase to 60 mg once daily if symptoms persist
  • Can further increase to 120 mg once daily
  • Maximum studied dose is 240 mg once daily 5, 6, 5

The 60 mg dose is the most widely studied and provides significant antianginal effects for approximately 12 hours after administration 4, 7.

Critical Timing Considerations

Take once daily in the morning only. This asymmetric dosing creates a nitrate-free interval overnight (approximately 12 hours), which is essential to prevent tolerance development 7, 8, 9. The medication provides effective prophylaxis throughout the day, with efficacy typically observed 1-12 hours after administration 4.

Never dose twice daily every 12 hours - this causes tolerance development and loss of efficacy 7.

Heart Failure Context

For heart failure with reduced ejection fraction (HFrEF), when using the combination of isosorbide dinitrate plus hydralazine (not Imdur specifically):

  • Fixed-dose combination: Start 20 mg isosorbide dinitrate/37.5 mg hydralazine three times daily, target 40 mg/75 mg three times daily 5, 6, 5
  • Separate components: Start 20-30 mg isosorbide dinitrate three times daily, target up to 120 mg total daily in divided doses 10, 5

Note that isosorbide mononitrate (Imdur) is not recommended for heart failure with preserved ejection fraction (HFpEF) - a well-designed trial showed patients were actually less active and had decreased quality of life compared to placebo 11.

Key Contraindications and Precautions

Absolute contraindications:

  • Systolic blood pressure <90 mmHg or >30 mmHg below baseline
  • Recent phosphodiesterase inhibitor use: sildenafil within 24 hours, tadalafil within 48 hours 1, 2, 3
  • Marked bradycardia or tachycardia

Blood pressure monitoring: Avoid titrating systolic BP below 110 mmHg in normotensive patients or >25% reduction in mean arterial pressure if hypertensive 1, 2, 3, 1.

Common Pitfalls to Avoid

  1. Don't abruptly discontinue after long-term use - this may exacerbate anginal symptoms; taper gradually 4

  2. Don't expect immediate tolerance prevention with all formulations - only once-daily extended-release preparations with morning dosing have proven sustained efficacy without tolerance at 6 weeks 7

  3. Headache management - This is the most common side effect but rarely requires discontinuation. It typically improves within days to weeks of continued therapy 4

  4. Don't use for acute angina relief - Imdur is for prophylaxis only. Patients still need sublingual nitroglycerin 0.3-0.6 mg as needed for acute episodes 1, 2, 3, 1

Pharmacokinetic Advantages

Isosorbide mononitrate has nearly 100% bioavailability with no first-pass metabolism, peak levels within 1 hour, and a half-life of approximately 5 hours 8. The extended-release formulation maintains therapeutic levels throughout the dosing interval while allowing the critical nitrate-free period overnight.

References

Research

Pharmacokinetics of isosorbide mononitrate.

The American journal of cardiology, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.